260315 general ahsn presentation updated smaller · ahsn*core*purpose*–health*and*wealth* •...
TRANSCRIPT
Introduc)on
Chief Execu)ve Officer: Professor Gary Ford CBE Chief Opera)ng Officer: Dr Paul Durrands
AHSN core purpose – health and wealth • Licensed by NHS England for 5 years to deliver four
objectives: • Focus on the needs of patients and local populations:
support and work in partnership with commissioners and public health bodies to identify and address unmet health and social care needs, whilst promoting health equality and best practice.
• Speed up adoption of innovation into practice to improve clinical outcomes and patient experience - support the identification and more rapid uptake and spread of research evidence and innovation at pace and scale to improve patient care and local population health.
• Build a culture of partnership and collaboration: promote inclusivity, partnership and collaboration to consider and address local, regional and national priorities.
• Create prosperity through co-development, testing, evaluation and early adoption and spread of new products and services.
The Oxford AHSN • Our Vision. Best health for our popula.on and prosperity for our region
• Our Mission. We will bring together universi.es, industry and the NHS to improve the health and prosperity of the Oxford region through rapid clinical innova.on adop.on
The Oxford AHSN • Strategy and objec)ves. Our strategy is to be facilita.ve and
work through our partners • We will build infrastructure and support the development of
people to accelerate innova.on and early adop.on in our NHS partners that improves health and adds value
• This will include funding clinical networks and developing teams for commercial development and innova.on adop.on to promote and accelerate change
• Our values. We will be inclusive, transparent and fair
What and where
http://www.oxfordahsn.org/our-work/wealth-creation/obn-map/ Oxford AHSN Life Sciences map link:
Oxford AHSN – 1 of 15 AHSNs 3.3M population Annual NHS spend circa £5bn NHS employees 65,000 326 GP practices, 2,000 GPs 11 Trusts 12 Clinical Commissioning Groups 4 Local Enterprise Partnerships 12 Councils Major international companies 569 healthcare and life science organisations Complex and varied landscape
Our health, university and LEP partners
New partnerships Universities
Life Science Industry
Wealth Creation Clinical Innovation
Adoption
Research & Development
Our 4 programmes support the interfaces of
all the partners
Patients and Public
Best Care
AHSNs, AHSCs and the research and innova)on landscape
INVENTION EVALUATION ADOPTION DIFFUSION
NIHR Infrastructure BRCs, BRUs, CRFs
NIHR Infrastructure CLAHRCs
AHSCs AHSNs
NHS Patient Care
NHS Patient Care
NIHR Infrastructure
Clinical Research Network
NIHR Programmes
MRC Programmes
Oxford AHSN governance structure
Programme Office
Oxford AHSN Board – Nigel Keen (Chair), Gary Ford (CEO) and Paul Durrands (COO) and oversight group chairs
AHSN Partnership
Council (annual general meeting open to all)
AHSN Partnership Board
(all NHS CEOs, HEI Leads, LEPs, CCGs, HETV, SCN, ABPI, ABHI, BIVDA) At least two meetings per year)
We welcome new partners Great Western Hospitals NHS FT is working with our clinical networks, R&D and Clinical InnovaAon AdopAon programmes. Bedford Hospital NHS Trust is working with the Imaging Network, has EBH Fellowship and was an OBN/AHSN Award winner. Frimley Health is engaged in Best Care, Clinical InnovaAon AdopAon programme, PaAent Safety and the Partnership Board.
Core team structure
CEO Gary Ford
Chair Nigel Keen
COO Paul Durrands
Execu.ve Assistant Jo-‐anne Harrison
Programme Officer Amy
Shearman
Programme offi
ce
Comms support Val Tate
The Oxford AHSN – 4 programmes 1. Best Care programme
• Clinical networks -‐ 10 AHSN funded and working with Thames Valley Strategic Clinical Networks
• Con)nuous learning – working with Health Educa.on Thames Valley • Fellowships in Evidence Based Healthcare
2. Clinical Innova)on Adop)on programme – adop.on at scale of innova.ons to improve pa.ent outcomes, experience and safety. Clinically led, working with NHS providers and industry
3. Research and Development programme -‐ work with Thames Valley and South Midlands Local CRN, NIHR, CLAHRC, life science industry and other research infrastructure
4. Wealth Crea)on programme -‐ help the region become the favoured loca.on for inward life science investment, life science business crea.on and growth
Best Care The Oxford AHSN is funding and suppor.ng 10 clinical networks for making improvements in health. We also work closely with the Thames Valley Strategic Clinical Networks (SCN)
1. Anxiety and Depression 2. Children 3. Demen)a 4. Diabetes 5. Early interven)on in mental health 6. Imaging 7. Maternity 8. Medicines op)misa)on 9. Mental and physical comorbidity 10. Out of Hospital Care
Mr Chand i Ra tna tunga , Associate Medical Director at Oxford University Hospitals NHS Trust, is the Senior Responsible Office for the Best Care Programme. He has been involved in the Oxford AHSN since June 2012, working on the d e ve l opmen t o f c l i n i c a l networks, a unique feature of the Oxford AHSN.
Best Care Programme Structure – Clinical Networks Be
st Care Programme
Anxiety and Depression Children’s Demen)a Diabetes Early Interven)on in
Mental Health
Host Oxford Health Oxford University Hospitals Oxford Health Oxford University
Hospitals Oxford Health
Network Manager Ineke Wolsey Tim Gustafson TBD Chris Hille Sarah Amani
Clinical Lead(s) Prof David Clark Prof Andrew Pollard Dr Rupert McShane Dr Katharine Owen Dr Belinda Lennox Dr Mark Allsopp
PIDs (Projects)
• Reducing Unwarranted Varia.on
• Suppor.ng Local Service Innova.on and Dissemina.ng Successes
• Improving Immunisa.on Coverage
• Equity in Healthcare Delivery
• Research Facilita.on
• Reducing Varia.on in Care
• Data Capture Systems
• ΔG™ Nutraceu.cal
• Young People with Demen.a
• Tackling Varia.on in Diabetes Care
• Gesta.onal Diabetes Telehealth
• Young Adult Diabetes Service
• Islet Cell Transplanta.on
• Reducing Varia.on in Care
• Common Assessment
• Enhancing Care Con.nuity and Extending Model of Early Interven.on
• Research recruitment
Best Care Programme Structure – Clinical Networks Be
st Care Programme
Imaging Maternity Medicines Op)misa)on
Mental and physical Co-‐Morbidity
Out of Hospital Care
Host Oxford University Hospitals NHS Trust
Oxford University Hospitals NHS Trust
Oxford University Hospitals NHS Trust
Oxford University Hospitals NHS Trust
Oxford University Hospitals NHS Trust
Network Manager Jenni Lee Katherine Edwards David Tutcher Michelle Acum Damian Haywood
Clinical Lead(s) Prof Fergus Gleeson Mr Lawrence Impey Mr Bhulesh Vadher Prof Mike Sharpe Dr Daniel Lasserson
PIDs (Projects)
• Reducing Unwarranted Varia.on
• Specialist Opinion Network
• Imaging Trial Development and Delivery
• Early PET-‐CT for Lung Cancer
• Improving Foetal Medicine care and consistency
• Maternity informa.on sharing
• Reducing Unwarranted Varia.on
• QIPP and Waste Reduc.on Projects
• Providing Medicines Informa.on Knowledge on Discharge
• Developing Strategic Rela.onship with Pharmaceu.cal Industry Partners
• Iden.fying & Implemen.ng Best Care Model
• Improving & Expanding Out of Hospital Care Models for Acute Illness in Frail Pa.ents
Best Care Programme Structure – Con)nuous Learning Be
st Care Programme
Fellowships in Evidence Based Healthcare
Host University of Oxford Network Manager Ruth Davis Clinical Lead(s) Prof Carl Heneghan
PIDs (Projects)
• Evidence Based Healthcare MSc Fellowship Programme
Clinical networks tackle varia)on – Children’s • Report : “Varia.on in Paediatric Care in the Thames Valley”, Dr Craig McDonald. • Compared admission rates, day case rates and mean length of stay for 5 common paediatric
condi.ons and revealed significant varia.on within the Oxford AHSN region. • Admission rates: between 2.9 and 7.6 fold varia.on differences in admission rates across the
region. • CCG’s with significantly (>2SD) above the na.onal average in red • CCGs within 2 SD of the na.onal average are highlighted in amber • CCGs (<2SD) below the na.onal average are marked in green
Gastroenteri)s Bronchioli)s Asthma Pneumonia Fever / Sepsis (0-‐4) Fever / Sepsis (5-‐17)
Aylesbury Vale L0.001) .025) Bracknell and Ascot Chiltern Milton Keynes High Newbury and District 01) North & West Reading ) ) ) ) ) ) Oxfordshire ) ) ) ) Slough ) ) ) ) ) Reading ) Windsor, Ascot & Maidenhead 0.001) Wokingham ) ) )
Medicines control and monitoring with industry partners • Pilo.ng prepara.on for EU legisla.on (expected Spring 2015) on Falsified Medicines, with Aegate Ltd and
Oxford University • Authen.ca.on of medicines at point of dispensing using advanced product scanning and pack verifica.on • Involves pharmaceu.cal manufacturers, wholesalers, and community pharmacies, hospital pharmacies and
dispensing doctors across Oxfordshire • Adding value in the UK through ability to reduce errors in dispensing and administra.on processes • Collect data across popula.on on medicines consump.on and realise popula.on based medicines
op.misa.on
Falsified medicines proposed schema
Anxiety and Depression (IAPT) Clinical Network -‐ engagement right across the region Professor David Clark Clinical Lead, Anxiety and Depression Network, Oxford AHSN Professor Shirley Reynolds Clinical Lead, Anxiety and Depression Network, Oxford AHSN Ineke Wolsey Network Manager, Anxiety and Depression Network, Oxford AHSN Lord Richard Layard Director of Wellbeing Programme, London School of Economics Professor Gary Ford CBE Chief Execu.ve Officer, Oxford AHSN Dr Mark Allsop Consultant Psychiatrist, Berkshire Healthcare NHS Founda.on Trust
Joint lead, Oxford AHSN Early Interven.on in Mental Health
June Dent Clinical Lead, Psychological Therapies Pathway, Oxfordshire Consultant Clinical Psychologist
Judith Chapman Clinical Director Specialist Mental Health Services & Talking Therapies (IAPT), Berkshire
John Pimm Clinical Lead -‐ Buckinghamshire Psychological Therapies Pathway Consultant Clinical Psychologist
Jon Olsen Manager, IAPT and Psychological Services, Milton Keynes Lorraine Davies-‐Smith Clinical Lead, Luton Wellbeing Service
Consultant Systemic and Family Psychotherapist
Heather Salt
Sarah Gibbons
Pamela Duckerin
Costas Lambropoulos
Bronwen Taylor
Consultant Psychologist, Oxon
Psychological Wellbeing Prac..oner Lead co-‐ordinator, Berks
High Intensity Therapist and Long Term Condi.ons Lead, Berks
High Intensity Therapist and PPiPCare Lead, Bucks
High Intensity Therapist and Breath Well Lead, Bucks Ailsa Harrison Pa.ent Representa.ve A&D Network Board Member
Best Care Oversight Group • Joe Harrison, CEO, Milton Keynes Hospital, Chair • Chandi Ratnatunga, Senior Responsible Owner (SRO) • Tina Kenny Medical Director, Buckinghamshire Healthcare • Catherine Stoddart, Chief Nurse, Oxford University Hospitals • Helen McKenzie, Director of Nursing, Berkshire Healthcare • David Buckle, Medical Director, NHS Central Southern CSU • Graham Jackson, Clinical Chair, Aylesbury Vale CCG • Joe McManners, Clinical Chair, Oxfordshire CCG • Muir Gray, Director, Bejer Value Healthcare • Jim Davis, Professor of Sokware Engineering, University of Oxford • Angela Coulter, Senior Research Scien.st, HSRU, University of Oxford • Nigel Edwards CEO, Nuffield Trust • Nicola Walsh, Assistant Director Leadership, King’s Fund • Paul Durrands COO, Oxford AHSN • Will Pank Best Care Programme Manager, Oxford AHSN
The Clinical Innova.on Adop.on (CIA) programme has evaluated around 200 innova.ons taking account of poten.al benefits, impact on pa.ent experience, local priori.es and ease of implementa.on. A final shortlist of ten, drawn from various sources including the Oxford AHSN clinical networks, local providers, na.onal awards and Na.onal Ins.tute for Health and Care Excellence (NICE) Technology Appraisal (TA) recommenda.ons – was approved by the Oxford AHSN Board and are being adopted across our region in 2014/15.
Clinical Innovation Adoption
Tracey Marrio3, Director of Clinical InnovaAon AdopAon. Tracey is leading the Programme for the Oxford AHSN, working closely with the Oxford AHSN clinical networks, providers, commissioners and suppliers for innovaAon implementaAon.
Oxford AHSN NHS partners strategic priori)es
0
2
4
6
8
10
12
14 High Quality Care
Pa)ent Safety
Leadership and Governance
Integrated Care
Working in Networks
Innova)on
Financial Stability
Pa)ent Experience Effec)ve Workforce
Develop Primary Care Led Services
Develop Preventa)ve Care Community
Elderly Care
Hospital Avoidance
Reduce Mortality
Long Term Condi)ons Management
Total Providers Total CCG
CIA – innova)ons for 14/15 1. CAUTI bladder scanner – reduce urinary tract infec)ons 2. ECG Monitor -‐ moving care closer to home
3. Electronic blood transfusion – pa)ent safety and waste reduc)on 4. Intermijent pneuma.c compression stockings – reduce risk of mortality
5. SHaRON (adults with ea.ng disorders) – beier clinical engagement and experience
6. NICE TA -‐ Alzheimer's – improved pa)ent outcome and carer experience
7. NICE TA -‐ Rheumatoid arthri.s – improved pa)ent outcome and experience
8. NICE TA -‐ AF, warfarin, an.coagulants -‐ reduce risk of DVT/Pulmonary Embolism
9. NICE TA -‐ Renal cancer -‐ improved survival
10. Intra opera.ve fluid management -‐ pa)ent safety and recovery
11. Gesta.onal diabetes Management – pa)ent experience and reduced clinic )me
CIA Oversight Group Role Name Title
Chair Anne Eden CEO – Buckinghamshire Health
Senior Responsible Owner (SRO) Best Care Chandi Ratnatunga Consultant Cardiothoracic Surgeon – Oxford University Hospitals
CIA Programme Director Tracey Marrioj Director of Clinical Innova.on Adop.on – Oxford AHSN
Senior Business Lead Paul Durrands Chief Opera.ng Officer – Oxford AHSN
Provider Medical Director Brian Reid Mr Brian Reid – Medical Director – Royal Berkshire Hospital
Provider Director of Nursing Catherine Stoddart Director of Nursing – Oxford University Hospitals
Provider Director of Finance Alex Gild Director of Finance – Berkshire Healthcare
Provider Procurement lead Wayne Preston Director of Finance and Procurement – Buckinghamshire Health
Provider Chief Opera.ng Officer Lisa Glynn Chief Opera.ng Officer – Heatherwood & Wexham Park Hospitals
Commissioner Finance lead Janet Meek Director of Finance, Berkshire West CCG Federa.on
Academic Lead Clinical Nursing Prac.ce Susan Procter Clinical Nursing Lead, Buckinghamshire New University
Academic Lead Diagnos.cs & Primary Care Carl Heneghan Professor and Director of Centre for Evidence Based Medicine, University of Oxford. Also Co-‐Director Diagnos.c Evalua.on Collabora.ve
Academic Lead Innova.on Adop.on Clive Savory Open University – Communica.ons & System Department
Academic Lead Pa.ent Safety Charles Vincent Professor of Psychology – Department of Experimental Psychology
Oxford AHSN Medicines Op.misa.on Network Lead
Bhulesh Vadher Chief Pharmacist – Oxford University Hospitals
Senior Lecturer Marke.ng and Course – Leader PR & MarCom
Bill Nichols Director – Centre for Health Communica.ons Research Buckinghamshire New University
CIA Case study -‐ Gesta)onal Diabetes The Health Need and Benefits • Increasing numbers of women with 3rd
Trimester Gestational Diabetes requiring clinical monitoring
Benefits • Assists with patient self management • Remote clinical monitoring with alerts • Regular opportunity to communicate with
patient • Reduction in unnecessary clinic visits so
increased capacity • Further research underway on impact on
difficult births and birth defects. Developed as a collaboration between OUH (Lucy McKillop) and Institute of Biomedical Engineering at the University of Oxford (Lionel Tarassenko)
Trusts 2014/15 2015/16Ox Uni Hosp !Royal Berks Hosp !Milton Keynes !Frimley Health UnderwayBucks Healthcare PlannedGreat Western PlannedBedford Planned
Roll Out Completed and Planned
Poten.al savings to the NHS in Oxford AHSN region of £700k full adop.on of technology
Project Objec)ves: 1. Increase the relevant adop)on of Intra Opera)ve Fluid Management Technology across
the region 2. Understand the barriers to adop)on from perspec)ve of NHS Providers, NHS
Commissioners, Industry 3. Design and develop a useful tool that providers and commissioners can use for business
planning, service development and contract management 4. Provide feedback to NHS England to inform na)onal policy
Es)mated 47,000 people in Oxford AHSN region could benefit from full
implementa)on of IOFM
technology
Expected Pa)ent Outcomes:
Providing senior doctors and nurses informa)on to assist clinical prac)ce and departmental management, based on robust evidence. The expected pa)ent outcomes are: • Reduce rate of re-‐admission and re-‐opera)on • Fewer post opera)ve complica)ons • Reduce emergency admissions into intensive care amer surgery • Low risk of cardiac complica)ons minimally or non-‐invasive monitoring • Reduce risk of catheter (CVP, arterial, PAC) related infec)on • Reduce length of hospital stay, pa)ents are ‘fit for discharge sooner’
Par)cipa)ng: Royal Berkshire Hospital, Frimley Health , Bucks Healthcare, Milton
Keynes Hospital, Bedford Hospital, Oxford
University Hospitals, Great Western Hospitals,
Central Manchester Hospitals
Poten.al savings to the NHS in Oxford AHSN £24.3M full adop.on of technology
April 14
• Project Selected and supported by RIF Fund
May
• Set up collabora.on with NHS Benchmarking Network to delivery the project
June
• Project launch across the Oxford AHSN region. NHS England agree to par.cipate in project.
Sept
• Clinical Regional Workshop hosted to design benchmarking dataset
Oct
• Suppliers engaged to understand barriers to adop.on
Nov -‐Dec
• IOFM Benchmarking Dataset launched with qualita.ve survey
March
• Presen.ng ini.al findings at the Na.onal Theatre Benchmarking Conference in London
April 15
• Na.onal rollout of IOFM project as part of the Na.onal Theatre Benchmarking Project
Intra Opera)ve Fluid Management Clinical Leader – Dr Emmanuel Umerah, Frimley Health
Prof Gary A Ford CBE is Chief ExecuAve Officer of the Oxford AHSN. Gary has led the adopAon of innovaAon in stroke care for many years. He remains a pracAsing clinician as a Consultant Stroke Physician at Oxford University Hospitals NHS Trust. He is also Director of the NaAonal InsAtute for Health Research (NIHR) Stroke Research Network.
• Brings together leads from Universi.es and NHS partners
• NHS partners to each develop R&D strategies
• Grow commercial research base and income across the NHS Trusts
• Close links with Clinical Research Network (LCRN) and the Collabora.on for Leadership in Applied Health Research and Care (CLAHRC)
• Cross working with the Oxford Academic Health Science Centre (AHSC) – one of 6 leaders in research
Research & Development
Big Data: Delivering the Digital Medicine Revolu.on
Building Novel NHS, University and Industry Rela.onships
Modula.ng Immune
Response for Pa.ent Benefit
Managing the Epidemic of Chronic Disease
Emerging Infec.ons & An.microbial Resistance
Cogni.ve Health:
Maintaining Cogni.ve Func.on in Health and Disease
Oxford Academic Health Science
Centre -‐ world leading research in
healthcare and life sciences
R & D Oversight Group University Research lead/alternate Chairman, Oxford University Hospitals Sir Jonathan Michael University of Oxford Professor Alastair Buchan University of Reading Dr Ben Whalley Buckinghamshire New University Professor Susan Procter The Open University Dr Nacho Romero / Dr Claire Turner The University of West London Professor Heather Loveday/Dr Jennie Wilson Oxford Brookes University Professor Linda King (Mary Boulton/Helen Dawes) University of Buckingham Professor Mike Cawthorne University of Bedfordshire Professor Mike Fisher Cranfield University TBC Oxford University Hospitals Prof Keith Channon Oxford Health Prof John Geddes Berkshire Healthcare Dr Jus.n Wilson Heatherwood and Wexham Park Dr Rob Loveland Royal Berkshire Dr Atul Kapila South Central Ambulance Service Mr Will Hancock/John Black Central and North West London Dr Alex Lewis Milton Keynes Mr Mar.n Wetherill Great Western Dr David Collins Buckinghamshire Healthcare Dr Helen Eagleton Bedford Hospital Dr Coleje Marshall Southern Health Dr Helen McCormack Health Educa)on Thames Valley/Oxford University Clinical Academic Graduate School
Professor Chris Pugh
South Midland and Thames Valley Clinical Research Network Dr Belinda Lennox/Dr Andrew Protheroe Collabora)on for Leadership in Applied Health Research Professor Richard Hobbs/Dr Belinda Lennox
Wealth Creation
Dr Nick Sco3-‐Ram MBE, Director of Commercial Development, has over 25 years experience in commercial and business development in the life sciences sector. Nick was awarded the MBE for services to biotechnology in 2001.
The Wealth Crea.on Programme will help the region become the favoured loca.on for life science investment, life science business crea.on and growth, helping the NHS – through the Oxford AHSN’s Clinical Innova.on Adop.on programme and Clinical Networks – to accelerate the adop.on of proven innova.ons which will bring significant benefit to pa.ents.
The Oxford AHSN wealth crea.on strategy is for, and on behalf of, our member organisa.ons – the NHS, Local Enterprise Partnerships (LEPs), Universi.es and industry – and the popula.on who all share an interest in economic growth across the region.
Oxford AHSN Wealth Crea)on
Types of Medical Innovation Any new product or service that delivers benefit to patients
• Pharmaceuticals – New drugs or new uses for established drugs • Vaccines • ATMP (Advanced Therapy Medicinal Products) – Gene or cell therapies • Tissue engineered products and regenerative medicine • Surgical innovations • Medical diagnostics and devices • Information Technology, medical informatics, mHealth and eHealth • Clinical decision making and support including IT tools to support compliance with best practice • Healthcare delivery, management and administration • Health promotion & disease prevention and patient driven wellness (public health)
Outbound Innovation Helping to ensure that great ideas from the NHS, universities and industry are converted into products and services
that create value for patients within and beyond our region
Inbound Innovation Informing the NHS about high value
innovations and enabling staff to make full use of them to improve outcomes
and experiences of patients
Wealth crea)on – key priori)es • Suppor)ng companies along the adop)on pathway
• Clear innova.on pathways from origina.on to adop.on highligh.ng health benefits and alignment with NHS needs
• Benefits to large and small businesses
• Suppor)ng investment into the region • Regional investment fund • Grant support – SBRI, Horizon 2020, Innovate UK
• Building a culture of innova)on in the NHS • Entrepreneurs boot camp • Challenge 2023
• Building long-‐term partnerships with businesses & other organisa)ons • SMEs & large companies
Over 40 projects in progress
Suppor)ng companies along the adop)on pathway • 14 projects with companies
• Large companies • Implementa.on study for BNP in ambulatory clinic
• Pathway analysis of GBS test in neonatal clinics
• SMEs • £1 million SBRI award in POC fluoropolymer
capillary film plavorm for acute coronary syndrome
• Pilot study in local Trusts for IU technology audit
• SBRI award winning plavorm for vital signs monitoring in pa.ents
• TTOs • Review of diagnos.cs porvolio for clinical/NHS
opportuni.es
Building investment opportuni)es across the region • 15 projects across the region
• Regional Investment Fund • GE Healthcare Finnamore
• The Alumni Summit
• Oxford Smart City
• Buckinghamshire Life Sciences Business Plan
• Structural Genomics Consor)um • Spin-‐out opportuni.es – inflamma.on
Oxford AHSN | October 2014 Copyright © 1992-2014 GE Healthcare Finnamore
21
Section 3: Structure of the innovation and investment system
Innovation Investment
Fund (IIF)
Fund Manager
Innovation Investment Company
(IIC)
NHS England
Corporate(Sponsorship(
Oxford(AHSN(
Sponsorship/(Funding(
LP(Investor(
LP(AHSN(
Due(Diligence(And(Negotiation(
Venture(Board(Representation(
Investment(Committee(
Investor(Relations(
��������(Funds(
Opportunity(Screening(
Post(investment(Venture(Management(
Support(
PreFNICE(Assessment(Trial(Design(Support(
NHS(Procurement(&(Deployment(Planning(
Opportunity(Origination(
NHS(Asset(and(Capability(Matching((
Oxford AHSN
Innovation and Commercialisation Funding
Corporate Sponsor: � Board(membership(� Technical(advisory(� Pipeline(review(
Wealth crea)on – Apps and e-‐health lab • Commissioned App Development Roadmap • Oxford e-‐health Lab – mul.-‐partner coordina.ng
hub for e-‐health ac.vity and accelera.on of innova.on and implementa.on
• Local App examples: • AED Locator (find a defibrillator) • Foodswitch – calorie and salt control • Monster Manor – blood sugar control for children with
Type 1 Diabetes
Projects with deliverables by March 2015 • Capillary Film Technology
• Helped company develop programme and secure £1 million SBRI award
• Intelligent Ultrasound • Pilot study for quality assessment of IU
images
• Innova)on Adop)on Workshop • Pilot workshop for industry
• Structural Genomics Consor)um • Business plan for spin out in
• New pre-‐compe))ve pathways for drug discovery
• Open access IP workshop
• Precision Medicine Catapult • AHSN lead on proposals for loca.ng in
Oxford region
• Forma)on of Oxford AHSN Diagnos)cs Advisory Council
• Focus for industry interac.ons with NHS – Dx companies in region comprise over 80% global market share
• Entrepreneurs Boot Camp • Course for clinicians and healthcare workers
• Sustainability and carbon reduc)on benchmarking programme
• Provide baseline for feasibility studies for 6 centres to be taken forward
• BIVDA Point of Care Working Group • Hosted mee.ng on commissioning,
Abingdon EMU & OUH clinical diagnos.cs
Wealth Crea)on Oversight Group
Wealth Crea.on Oversight Group
Berkshire Working Group for Wealth
Crea.on
Buckinghamshire Working Group for Wealth Crea.on
Oxfordshire Working Group for Wealth Crea.on
Chairman Dr Nick Edwards – MedInnovate
Professor Chas Bountra – SGC John Collins – CIMIT Martin Hunt – i4i
Martino Picardo – SBC Bruce Potter – Blake Morgan Nigel Tipple – Oxfordshire LEP
Oxford AHSN – 3 themes • Informa.cs • Pa.ent and Public Involvement, Engagement and Experience • Pa.ent Safety
Informatics Mike Denis, Director of Informa.on Strategy and Governance, has a dual role across the Oxford AHSN and Oxford AHSC and provides strategic leadership in linking core business goals through informa.cs and technology innova.on, whilst providing cri.cal contribu.on to the Oxford AHSN and Oxford AHSC partners’ strategies Informa.cs is a cross-‐cuxng theme, linking core business goals through technology innova.on, both within the Oxford AHSN and with partner organisa.ons Informa.cs supports data analysis requirements and develop appropriate Informa.on Governance arrangements to facilitate data sharing and exchange. We help to facilitate pa.ent recruitment to research studies and clinical trials and extend programme research databases across organisa.ons in primary, community and acute services
Mike Den is , D i rector o f InformaAon Strategy, has over 26 years experience working in NHS health informaAcs. He previously held a similar role at t h e S o u t h L o n d o n a n d Maudsley NHS FoundaAon Trust.
Informa)cs • A cross cuxng theme of the AHSN • Exploi.ng the value of data for service improvement and
research • A hybrid model for Informa.cs
Delivery -‐ January 2015 In collabora.on with:
Informa)cs Oversight Group Aiendees Organisa)on
Stuart Bell, Chairman Chief Execu.ve, Oxford Health NHS FT
Chris Bunch Consultant Physician and Caldicoj Guardian, Oxford University Hospitals
Michael Seres Pa.ent representa.ve
Gary Ford Chief Execu.ve, Oxford AHSN
Paul Durrands Chief Opera.ng Officer, Oxford AHSN
Caroline Hargrove McClaren
Paul King Microsok
Simon O’Shaughnessy Novo Nordisk
Paul Lindley-‐Scoj Open University
Scoj Pejy Vodafone
Patient and Public Involvement, Engagement and Experience (PPIEE)
Dr Sian Rees is the lead for PaAent and Public Involvement, Engagement and Experience, working with colleagues in Trusts across the Oxford AHSN, and the NHS England Area Team, Health EducaAon Thames Valley and the CLAHRC. In parAcular, she will support this area of acAvity in each of the developing clinical networks.
The Oxford AHSN is working to embed partnership with pa.ents and the public across its work programmes. Each of the clinical networks is developing plans for PPIEE. The PPIEE Theme is a joint produc.on with the Thames Valley Local Area team and Strategic Clinical Networks
What do we mean by involvement? How pa.ents and the public will be involved in the structures and processes of the work i.e. though mechanisms such as governance, priority sexng, teaching and educa.on, iden.fica.on of the need for innova.on, assessment of technologies. What do we mean by engagement? How pa.ents and their carers will be supported to be ac.ve par.cipants in their own care through approaches such as personalised care planning and shared decision-‐making. What do we mean by experience? How the subjec.ve experience of pa.ents is captured and u.lised for quality improvement.
Patient Safety
Professor Charles Vincent leads the PaDent Safety CollaboraDve, launched in October 2014. Charles trained as a clinical psychologist and has worked in the field of the causes of harm to paDents and the consequences for paDents and staff for many years.
The Pa.ent Safety Collabora.ve (PSC) was launched in October 2014 – part of a network of 15 covering England. It will focus ini.ally on a small number of clinical programmes but also act as an umbrella and coordina.ng centre for the many important pa.ent safety ini.a.ves – both prac.ce and research – within Berkshire, Buckinghamshire, Oxfordshire and Bedford. The principal aims of the PSC are to: • Develop safety from its present narrow focus on hospital medicine to
embrace the en.re pa.ent pathway • Develop and sustain clinical safety improvement programmes within the
Oxford AHSN • Develop ini.a.ves to build safer clinical systems across the Oxford AHSN • Collaborate and support sister safety programmes both na.onally and
interna.onally. Early priori.es include the ac.ve engagement of pa.ents and carers; the development of a safety informa.on system, the establishment and support of programmes on acute kidney injury, medica)on safety, pressure ulcers and safety in mental health and developing capacity and capability in leadership for safety improvement. • PSC has appointed Jill Bailey as Head of Pa.ent Safety
Pa)ent Safety Academy • The work of the Pa.ent Safety Academy, led by Co-‐Directors, Professor Peter McCulloch and Dr Helen Higham, focuses on: • Human factors training • Training for Surgical teams • Development of Programmes in Mental Health & Primary Care
• Training for Trust Management and Boards
Pa)ent Safety Oversight Group • Plans are being developed for the Oversight Group for pa.ent safety – this will include stakeholders from across the Oxford AHSN
Contact details: Megan Turmezei Director of Corporate Affairs Oxford AHSN The Magdalen Centre Robert Robinson Avenue OXFORD SCIENCE PARK OX4 4GA [email protected] T: 01865 784958 M: 07837 401519 www.Oxfordahsn.org
Newsleier: http://www.oxfordahsn.org/news-and-events/network-newsletters/
Annual report: http://www.oxfordahsn.org/wp-content/uploads/2014/06/Oxford_AHSN_Annual_Report_2014.pdf